Скачать или смотреть Indatuximab Advancing CD138-Targeted Therapy in Cancer Research

https://www.assaygenie.com/anti-cd138...

Most Important Ideas/Facts:

Indatuximab ravtansine is an ADC that targets CD138: "Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly expressed on the surface of certain cancer cells, including multiple myeloma and some solid tumors." This identifies the drug and its target.

CD138 as a therapeutic target: CD138 (syndecan-1) is a cell surface protein overexpressed in multiple myeloma and other malignancies. It plays a crucial role in cell adhesion, migration, and signaling, making it a "valuable and strategic target for therapeutic intervention."

Mechanism of Action - Targeted Delivery and Cytotoxicity: The ADC selectively binds to CD138, is internalized, and releases DM4, a cytotoxic payload. This payload "disrupts microtubule dynamics, leading to cell cycle arrest and subsequent apoptosis of the cancer cell." This selective delivery is intended to "minimize off-target effects and reduces systemic toxicity."
Clinical Trials in RRMM: Indatuximab ravtansine has shown "promising results...in relapsed and refractory multiple myeloma (RRMM)." Combinations with agents like pomalidomide and dexamethasone have demonstrated "improved response rates and progression-free survival."

Potential in RCC: The therapy is also being investigated for renal cell carcinoma (RCC), "a malignancy with limited targeted therapies," indicating its potential to expand beyond hematological cancers.

Research Focus: Ongoing research aims to optimize the drug's "safety profile, determine its most effective dosing strategies, and explore its utility in combination regimens."

Indatuximab Biosimilar: A biosimilar version of indatuximab is available for research use, providing a "high-quality, research-use-only alternative to the original drug" and enabling "in-depth exploration of CD138-related pathways and ADC mechanisms." The biosimilar is "not intended for diagnostic or therapeutic purposes."